Background: Fetal growth restriction, i.e. the restriction of genetically predetermined growth potential due to placental dysfunction, is a major cause of neonatal morbidity and mortality. The consequences of inadequate fetal growth can be life-long, but the risks can be reduced substantially if the condition is identified prenatally. Currently, screening strategies are based on ultrasound detection of a small-for-gestational age fetus and do not take into account the underlying vascular pathology in the placenta. Measurement of maternal circulating angiogenic biomarkers placental growth factor, sFlt-1 (soluble FMS-like tyrosine kinase-1) are increasingly used in studies on fetal growth restriction as they reflect the pathophysiological process in the placenta. However, interpretation of the role of angiogenic biomarkers in prediction of fetal growth restriction is hampered by the varying design, population, timing, assay technique and cut-off values used in these studies. Methods: We conducted a systematic-review in PubMed (MEDLINE), EMBASE (Ovid) and Cochrane to explore the predictive performance of maternal concentrations of placental growth factor, sFlt-1 and their ratio for fetal growth restriction and small-for-gestational age, at different gestational ages, and describe the longitudinal changes in biomarker concentrations and optimal discriminatory cut-off values. Results: We included 26 studies with 2514 cases with small-for-gestational age, 27 cases of fetal growth restriction, 582 cases mixed small-for-gestational age/fetal growth restriction and 29,374 reference. The largest mean differences for the two biomarkers and their ratio were found after 26 weeks of gestational age and not in the first trimester. The ROC-AUC varied between 0.60 and 0.89 with sensitivity and specificity matching the different cut-off values or a preset false-positive rate of 10%. Conclusions: Most of the studies did not make a distinction between small-for-gestational age and fetal growth restriction, and therefore the small-for-gestational age group consists of fetuses with growth restriction and fetuses that are constitutionally normal. The biomarkers can be a valuable screening tool for small-for-gestational age pregnancies, but unfortunately, there is not yet a clear cut-off value to use for screening. More research is needed to see if these biomarkers are sufficiently able to differentiate growth restriction on their own and how these biomarkers in combination with other relevant clinical and ultrasound parameters can be used in clinical routine diagnostics.
Introduction
It has long been acknowledged that small-forgestational age (SGA) neonates are at increased risk of perinatal mortality and morbidity and have a higher risk of developing disabilities in childhood, and severe cardiovascular and metabolic diseases later in life. 1, 2 The obvious reason is that, among the SGA neonates, a subgroup has suffered from intrauterine or fetal growth restriction (FGR), the rest being healthy and constitutionally small due to their demographic factors. Neonates with FGR have failed to reach their genetically predetermined growth potential due to placental dysfunction. The consequences of inadequate fetal growth can be life-long, but the risk of perinatal morbidity and mortality can be reduced substantially if the condition is identified prenatally. 1, 3 An optimal screening strategy for the prediction of SGA and mainly those with fetal growth restriction is highly desirable. 4, 5 Currently, screening strategies focus on antenatal ultrasound to detect small fetuses, defined as a fetal abdominal circumference or an estimated fetal weight (EFW) below the 10th percentile. However, this ultrasound-based strategy ignores the underlying pathological process in the placenta that leads to suboptimal supply of nutrients to the growing fetus. Abnormal vascular growth and transformation in the placenta can create a high vessel resistance network that has been associated with the development of fetal growth restriction and also pre-eclampsia. 6 The vascular endothelial growth factor (VEGF) family plays a major role in regulating vasculogenesis and angiogenesis in early human placentation. 7 Placental growth factor (PlGF) is a pro-angiogenic factor predominantly expressed in placental trophoblast and binds to VEGF-receptor or fms-like tyrosine-1 (Flt1), thereby enhancing the pro-angiogenic action of VEGF-A. Besides this membrane-bound receptor form, Flt-1 also exists in a soluble form (sFlt-1), which is secreted by the placenta and scavenges VEGF and PlGF, thereby lowering circulating concentrations of unbound VEGF and PlGF. Reduced placental perfusion and subsequent placental hypoxia are associated with increased production of sFlt-1 and decreased concentrations of PlGF in both human and animal models. 8 This altered balance in pro-/anti-angiogenic factors is postulated to cause generalized endothelial dysfunction that is characteristic of pre-eclampsia which makes endothelial dysfunction a hallmark feature of pre-eclampsia. Fetal growth restriction has pathophysiological features in common with pre-eclampsia. Therefore, it was conceivable that measuring these placental biomarkers in maternal blood could be used in the prediction of pre-eclampsia and fetal growth restriction. 6, 9 The serum sFlt-1/PlGF ratio has already been used in improving the clinical management for preeclampsia. Pre-eclampsia is defined as the new onset of hypertension and proteinuria after 20 weeks of gestation. This disorder is associated with a high risk of fetal growth restriction and maternal morbidity. A low sFlt-1/PlGF ratio was highly predictive for ruling out pre-eclampsia and avoiding unnecessary hospitalization with a significant economic impact. 10 At this moment, there is no conclusive evidence that measuring maternal angiogenic biomarkers are (also) useful in the clinical management of fetal growth restriction. Despite many studies linking maternal angiogenic concentrations to the neonatal outcomes (mainly SGA), 3, [11] [12] [13] [14] [15] [16] there is no systematic review of the predictive performance of PlGF, sFlt-1 and sFlt-1/PlGF ratio at different trimesters of pregnancy.
The main purpose of this systematic review is to assess studies that evaluate the predictive performance of placental angiogenic biomarkers (PlGF, sFlt-1 and/ or the sFlt-1/PlGF ratio) for SGA and fetal growth restriction. First, we will describe differences in serum biomarker concentrations between SGA and reference pregnancies at different gestational age (GA) periods. Next, we will present the longitudinal trajectories of PlGF, sFlt-1 and their ratio for SGA and reference pregnancies. And third, we evaluate the prognostic performance of these biomarkers for the prediction of SGA.
Methods

Search strategy and eligibility criteria
We performed a systematic search according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015). 17 The databases PubMed (NCBI), EMBASE (Ovid) and the Cochrane Library were searched for original studies investigating the biomarkers PlGF, sFlt-1 and/or the sFlt-1/PlGF ratio in SGA or FGR, from database inception until 27 July 2018. Medical subject headings (MeSH) and text words that we used are listed in Supplementary Table 1 , which were combined with Boolean Operators: AND and OR. The included languages were English and Dutch. There was no restriction applied on the type of study. Exclusion criteria were studies where no full text was available, or those performed in multiple pregnancies, nonviable pregnancies, or the measurements being performed after the diagnosis of SGA/FGR was made, as this is in disagreement with the aim of the review. Studies were also excluded if they had no reference group without SGA, did not report absolute values, specific GA timing or the assay methods used of biomarker measurements. Additionally, the reference lists of the selected articles were screened to add all relevant studies. The study protocol was approved by the medical ethical committee of the Maastricht University Medical Centre (17-4- 
Study selection
An initial title and abstract review was performed by two independent reviewers (MH and AH), using Rayyan. 18 A third reviewer aided in the exclusion of duplicates and ineligible papers after first selection (S.A.). Next, two investigators analysed the full-text articles to determine their eligibility in the review (M.H. and A.H.) Any disagreement was resolved through discussion. If consensus could not be achieved, a third reviewer (S.A.) was consulted.
Data extraction
Data from the eligible studies were extracted by two independent reviewers (M.H. and A.H.) using a predesigned data collection form. The data on first author, publication year, country, type of study design, characteristics of the population studied, sample size, GA at sampling, cut-offs used, sensitivity, specificity, area under the curve and assay type. If information was missing, corresponding authors were contacted by email.
Quality assessment
The methodological quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. 19 The risk of bias is judged in four main domains: (1) patient selection, (2) index test, (3) reference standard and (4) flow of patients in the study and timing of the index test and the reference standard. Concerns about the applicability of the test for clinical practice are also judged in the first three domains.
Data synthesis
In order to be able to quantitatively assess the relationship between SGA or FGR and the biochemical markers, we converted data given in median or multiple of the median (MoM) with IQR to mean with SD, using an online calculator of the method devised by Hozo et al. 20 Next, the data were categorized by GA at time of sampling. The categories made are: 9-14 weeks, 15-25 weeks, 26-35 weeks and P36 weeks of GA, for both SGA and FGR definitions.
The primary outcome for each study was the mean difference in PlGF, sFlt-1 and their ratio between the SGA and reference group, reported with 95% confidence interval (CI).
The ratio between total variation due to heterogeneity and total variation (I 2 statistics) is presented as a measure for heterogeneity and was used to aid the decision between a fixed effect and random effects metaanalysis. I 2 can distinguish true heterogeneity from sampling variance and is expressed as a percentage. Sources of heterogeneity (assay of biomarker measurement, cut-off of SGA) and the difference between reference and SGA pregnancies could not be investigated by meta-regression analyses using a mixed-effects model because of the low amount of studies. Studies were pooled using inverse-variance weighting and were summarized using forest plots. The second outcome was the prognostic performance of these biomarkers and, if available, of the cut-off values to differentiate between SGA versus reference group. The last outcome was the presentation of the longitudinal levels of the PlGF, sFlt-1 and their ratio for SGA and reference pregnancies, with a difference in assay used. The meta-analyses were performed in R version 3.2.3 using the meta-package.
Results
Study and data selection
Our search identified a total of 593 studies ( Figure 1 ). After first selection by title and abstract, duplicates were removed and 489 studies were screened based on the title and abstract, leaving 43 full-text articles to be analysed in detail. In this phase, studies were excluded because of the following reasons: no reference group without SGA (n ¼ 9), no absolute values available full-text available (n ¼ 1), no specific defined GA range (n ¼ 1).
The 26 included articles analysed were published between 2005 and 2018, from all over the world. A total of 2514 cases of SGA, 27 cases of FGR and 582 cases of mixed SGA/FGR (i.e. both FGR were identified during pregnancy and SGA) were included, in addition to a total of 29,374 'reference' pregnancies used as controls in the different studies.
Study characteristics are presented in Table 1 . Most studies employed the case-control design 2,4,15,21-33 and 10 studies were prospective cohorts. 1, 3, 13, 14, 16, [34] [35] [36] [37] [38] The majority of studies recruited patients with SGA as outcome. [1] [2] [3] [4] [13] [14] [15] [16] [21] [22] [23] 25, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The definition for SGA was lower than the 10th birthweight percentiles upper reference limit in 18 studies. 3, 4, [13] [14] [15] [16] [21] [22] [23] 25, 26, [29] [30] [31] [32] 34, 35, 37 Five studies used the cut-off a birthweight lower than the 5th percentile. 1, 2, 28, 36, 38 One study used a birthweight lower than the 3rd percentile. 24 One study used a birthweight lower than 2 standard deviations as cut-off value. 33 One study used FGR: estimated fetal weight < 10th and an umbilical artery PI > 95th as cut-off value. 27 Three studies described a population with pre-eclampsia as comorbidity. This differs from 1.3 to 18.4% PE in the study population and 2.1-5.0% in the reference group. 4, 24, 31 The included studies used a variety of assay platforms from various manufacturers -15 used R&D systems, 3,4,21,23-25,28-33,35,37,38 6 studies used Roche Diagnostics, 1, 14, 15, 26, 27, 36 2 used Thermo Fisher, 2,13 1 study Beckman-Coulter, 34 1 study Alere, 21 1 study Bender Medsystems 22 and 1 study gave no information about the used assay. Full-text arƟcles excluded:
-no reference group without SGA (n=9) -no absolute values available (n=5) -no test method described (n=1) -no full text available (n=1) -no specific defined GA range (n=1) Figure 1 . Flowchart summarizing study selection process. 
Quality assessment
The quality assessment of the included studies is depicted in Supplementary Figure 1 . The majority of the studies were defined as good quality (n ¼ 17). The other studies were either of moderate quality (n ¼ 6) or low quality (n ¼ 3). In more studies the information about patient selection and/or biomarkers assays was not provided clearly.
PlGF measurements during SGA and reference pregnancy
Forest plots of PlGF measurements during SGA and normal pregnancy are depicted in Figure 2 . 
sFlt-1 measurements during SGA and reference pregnancy
There was no significant mean difference during first (n ¼ 8 studies) or second trimester (n ¼ 6) between SGA and reference group (Figure 3 ). After 26 weeks, SGA group had significantly higher sFlt-1 values compared with the reference group (n ¼ 8) with pooled mean difference of 307 pg/mL (95% CI: 9 to 605 pg/mL). The largest mean difference was found after 36 weeks (n ¼ 5) with a pooled mean difference of 1152 pg/mL (95% CI: 317 to 1988 pg/mL).
sFlt-1/PlGF ratio during SGA and reference pregnancy
The sFlt-1/PlGF measurement during SGA pregnancies compared with reference values are depicted in Figure 4 . No significant mean difference was found between SGA and reference for the sFlt-1/PlGF ratio during different GA intervals: < 14 weeks, 15-25 weeks and 26-36 weeks (n ¼ 5, 2 and 5 studies, respectively). The sFlt-1/PlGF ratio values were higher in the SGA group versus reference only after 36 weeks based on one study with a mean difference of 30.1 (95% CI: 24.8-35.4). PlGF longitudinal courses show the most significant differences between SGA and control pregnancies, which is in contrast with the sFLT-1 and ratio courses where differences between the two groups is minimal.
Longitudinal Course of PlGF, sFlt-1 and ratio during SGA pregnancy and reference
In Figures 5 to 7 , the longitudinal course of PlGF, sFlt-1 and the ratio are presented for both the SGA and the reference group. In reference pregnancies, PlGF concentrations were low in the first trimester, followed by a steady increase starting from 12 weeks till a peak around 30 weeks, followed by a sharp drop until term. SGA pregnancies had a similar but blunter curve with consistently lower PlGF concentrations, mainly between 24 and 36 weeks. Concentrations of sFlt-1 in reference pregnancies showed a dual peak, around 16 weeks and again after 30 weeks until term. SGA pregnancies had a grossly similar curve with demonstrably higher sFlt-1 concentrations after 30 weeks until term. The sFlt-1/PlGF ratio in reference pregnancies showed a steady decrease throughout pregnancy with a nadir around 30 weeks, and a slight shallow increase thereafter until term. Similar to the sFlt-1 curve, SGA pregnancies had grossly a similar curve for the sFlt-1/PlGF ratio with an earlier and steeper rise from 28 weeks onwards. 
Prognostic performance of the biomarkers
In Table 2 , studies reporting sensitivity, specificity, positive and negative predictive values and area under the receiver operating characteristic curve (AUC) for predicting FGR or SGA using PlGF (8 studies), sFlt-1 (4 studies), and sFlt-1/PlGF ratio (8 studies) were included. Pooled analysis of prediction parameters was not possible due to the different GA at sampling and different definitions used for SGA (birthweight <5th or <10th percentile) and FGR.
For PlGF only four of the eight studies reported cut-off values using different assays and for the two studies which used the Thermo Fisher assay also different cut-off values were used. The AUC values varied from 0.65 to 0.89, reflecting the wide range in cut-off values used: 34.7 (at 12 weeks) 13 to 252 (at 28 weeks). 14 For sFlt-1, two of the four studies reported cut-off values, and these two studies used different assay types. The AUC values vary from 0.61 to 0.74. For the sFlt-1/PlGF ratio, five out of eight studies reported cut-off values and sometimes more than one cut-off value was used. 14, 27 The AUC values vary from 0.55 to 0.89.
Five studies used a combination of maternal, fetal and biochemical factors in the prediction of SGA. In the first trimester, a model using serum PlGF concentrations, in combination with maternal factors, mean arterial pressure (MAP), pregnancy-associated plasma protein-A and beta-human chorionic gonadotropin had a prediction rate of 73% for early SGA (requiring delivery before 37 weeks) and 46% for late SGA (delivering at term) with a FPR of 10%. 38 A model using a combination of sFlt-1/PlGF ratio and a priori risk for SGA, MAP and uterine artery pulsatility index (UtA-PI) had a prediction rate of 42% for SGA and 66% for FGR, with a FPR of 10%. 24 In the third trimester, serum PlGF concentrations were used in two models in combination with maternal factors and EFW to predict SGA with a higher sensitivity for early SGA (delivering at 32-36 weeks) compared with late SGA (delivering > 37 weeks) and for severe SGA (birthweight < 3rd percentile) compared to <10th percentile. 1, 36 Using a combination of sFlt-1/PlGF ratio and EFW, the prediction rate for SGA was 45%, with a 10% FPR and AUC of 0.77 (95% CI: 0.70-0.85). 31 
Discussion
In this systematic review, we included 26 studies that investigated the values of measuring the angiogenic biomarkers PlGF, sFlt-1 and their ratio in pregnancies complicated by FGR or SGA. This is the first review to our knowledge that focused on studies describing biomarkers changes in SGA pregnancies. Using GA-specific intervals, the data analysis demonstrated that the mean differences between SGA and reference pregnancies were larger in serum concentration of PlGF than with sFlt-1 or their ratio, and were more profound during later stages of pregnancy (after 25 weeks) and not in the first trimester.
In the longitudinal course of biomarkers, there was a good discrimination between SGA and reference pregnancies especially during 24-36 weeks for PlGF, while for sFlt-1 and the sFlt-1/PlGF ratio, there was no discrimination between SGA and reference pregnancies as depicted by the overlapping confidence intervals. The amount of literature for sFlt-1 and the sFlt-1/PlGF ratio is limited and also heterogeneous which can result in a diminished discrimination between SGA and reference pregnancies for sFlt-1 and the sFlt-1/ PlGF ratio. Furthermore, screening with biomarkers for SGA showed a moderate predictive performance with a wide range of AUC that varied from 0.65-0.89 for PlGF, 0.55-0.89 for sFlt-1 and the PlGF/sFlt-1 ratio, reflecting the heterogeneity in outcome definition, assay methods and timing of screening.
Angiogenic biomarkers, as non-invasive and readily available indicators of placental function, have made a large impact on the way researchers nowadays understand and approach placental dysfunction disorders. 39 Since the earlier publications describing lower maternal serum PlGF and higher sFlt-1 concentrations in women with pre-eclampsia, 40 these biomarkers have increasingly claimed a prominent place in the clinical management of pre-eclampsia. Using a cut-off value of 38, the sFlt-1/PlGF ratio as proposed is a reliable predictor for the imminent development of preeclampsia. 10, 41 Since pre-eclampsia and FGR (fetal growth restriction) probably share a common underlying placental pathology, 42 we aimed in this review that identifying cut-off values for these biomarkers this could be of use to differentiate between pregnancies with or without FGR. Only 3 out of 26 studies had patients included with pre-eclampsia. Because of this relative low percentage, we could not perform a reliable analysis without PE. An optimal discriminatory cut-off value could not be calculated from published studies, neither for the outcome of FGR nor for SGA due to the limited number of studies reporting cut-off values used (4 out of 8 studies) and their heterogeneous setting. In addition, pooled analysis of prediction parameters was also not possible due to the different assay methods, different GA at sampling and different definitions used for SGA (birthweight <5th or <10th percentile) and FGR. Benton et al. 12 showed that low PlGF concentrations (<5th percentile for GA) had a good capacity (AUC of 0.96) to discriminate fetuses with placental disease from those who are constitutionally small. Using a GA-adjusted percentiles for PlGF could, therefore, improve clinical management of pregnancies with SGA by identifying the subgroup with an underlying placental pathology and ultimately form the highest risk group. We and others have demonstrated the added value of combining the measurement of placental biomarkers in the first trimester with clinical characteristics, Doppler parameters or fetal growth in the prediction of FGR. 38, 43, 44 The use of multiple parameters could increase the specificity and sensitivity of the screening, mainly because each biomarker reflect a different mechanistic pathway linked to the disease process. While abnormal uterine artery Doppler reflects the inadequate trophoblastic invasion of the maternal spiral arteries, abnormal serum concentrations of PlGF and sFlt-1 reflect the dysregulated secretory activity by placental trophoblasts, 6 both well recognized mechanisms linked to the development of FGR. Earlier screening, before evident clinical recognition is possible, may have the potential to improve the clinical management and reduced morbidity for both mother and fetus. Consequently, appropriate planning of follow-up visits and the timely commencement of therapeutic interventions, such as Aspirin is possible, with recent large trials reporting great success in reversing the natural outcome of placenta dysfunction. 45 This review highlights the importance of meticulous consideration of methodological aspects of studies, that might affect the interpretation of results. The considerable heterogeneity between the studies included, as reflected by high I 2 values in the forest plot analysis, could have various sources. Worldwide, different fetal and neonatal growth charts are used for defining FGR and SGA with varying cut-off values. It is difficult to define FGR, the fetus does not reach its biological growth potential as a consequence of impaired placental function. It is usually defined by the statistical deviation of fetal size from a population-based reference, with a threshold at the 10th, 5th of 3rd centile. However this threshold is better usable for SGA, based on actual weight at birth. Due to the lack of this gold standard to define FGR based on the underlying pathophysiology, SGA is used as an inappropriate proxy, that represents a heterogeneous group of both constitutionally small and growth restricted fetuses. 46 Growth-restricted fetuses with a birth weight > 10th centile, may not reach their growth potential, but remain undiagnosed because of the birthweight, with an increased risk of adverse outcome. Recently, consensus definitions have been reached by Delphi procedure for both early-onset and late-onset FGR. 47 These new definitions of FGR are useful for a prospective study in the future, many of the GA of sampling in meanAESD, or min-max; cut-off value in pg/mL; GA: gestational age at time of sampling; SGA: small-for-gestational-age; FGR: fetal growth restriction; AUC: area-under the curve; PPV: positive predictive value; NPV: negative predictive value; Data presented as mean, with 95% confidence interval (if available). *Data not available.
biomarker studies in this review have been published before the new definition. The heterogeneity could also be caused by varying study design and using different assays. The studies included in this review used different immunoassays for PlGF and sFlt-1. It is well known that standardization of immunoassays is difficult. A major problem in immunoassays is that the recognition of the analyte is determined by the reagent using a limited portion of the molecule. 48 Large differences in assay calibration can lead to misinterpretations of the clinical course when different assays are used. 49 For PlGF and sFlt-1 there is no reference method defined and there is no reference material, like a WHO standard available. The different antibodies which are used can have another specificity for the PlGF isoforms and to free and bound PlGF. In addition, the larger studies which included more than 100 SGA cases or controls were also based on R&D Systems and Roche assays. Although, there is no reference method or material available for PlGF and sFlt-1, it is described that the PlGF and sFlt-1 immunoassays of Roche Diagnostics are calibrated with recombinant human PIGF and sFlt-1 and standardized against the Quantikine PIGF and sFlt-1 ELISAs from R&D Systems. 50 The study of Schiettecatte et al., 2010 showed that there is good correlation between Roche and the Quantikine ELISA R&D Systems. 51 The Kryptor/Thermo Fisher PlGF method is also calibrated with recombinant human PlGF and standardized against the Quantikine PlGF ELISA from R&D system. The Kryptor sFlt-1 method is standardized against the Roche method. 52 The study of Helden et al., 2015 confirmed a good correlation between Kryptor and Roche assay. 53 So we can conclude that the results of the R&D system, Roche and Thermo Fisher assays are very similar because they are standardized against each other. 54 
Conclusions
In conclusion, this review outlines the differences in angiogenic biomarker concentrations in SGA/FGR pregnancies, similar to earlier reviews on the related placental disorder of pre-eclampsia. Despite variation in study design and test methods, angiogenic biomarkers showed different mean levels and longitudinal trends in SGA pregnancies. Further research should focus on improving the prediction of at-risk SGA pregnancies by combining placental biomarkers with clinical characteristics and ultrasound measures of fetal growth velocity.
